Table 1.
Subjects’ baseline characteristics
| Characteristic | n (%) or median (range) |
|---|---|
| Age, y | 63 (50 to 77) |
| Age by decade, y | |
| 50 to 59 | 106 (32) |
| 60 to 69 | 166 (50) |
| 70+ | 58 (18) |
| Female sex | 132 (40) |
| Race | |
| White | 294 (89) |
| African American | 13 (4) |
| Asian | 11 (3) |
| >1 race | 1 (<1) |
| Missing | 11 (3) |
| Non-Hispanic ethnicity | 306 (93) |
| Disease type | |
| AML | 151 (46) |
| MDS/MPN | 109 (33) |
| NHL | 23 (7) |
| ALL | 21 (6) |
| Other leukemia | 12 (4) |
| CML | 9 (3) |
| PCD/MM | 5 (2) |
| DRI 25 | |
| Low | 21 (6) |
| Intermediate | 189 (57) |
| High | 84 (25) |
| Very high | 5 (2) |
| Unknown | 31 (9) |
| Karnofsky performance score | |
| 90 to 100 | 241 (73) |
| <90 | 83 (25) |
| Missing | 6 (2) |
| HCT-CI score | |
| 0 | 66 (20) |
| 1 | 44 (13) |
| 2 | 52 (16) |
| 3+ | 167 (51) |
| Missing | 1 (<1) |
| Donor type | |
| Matched sibling | 110 (33) |
| Other related* | 13 (4) |
| Well-matched unrelated; 8/8 match | 139 (42) |
| Partially matched unrelated; 7/8 match | 29 (9) |
| Cord blood | 39 (12) |
| Conditioning intensity | |
| Myeloablative conditioning | 105 (32) |
| Reduced intensity conditioning | 224 (68) |
| Missing | 1 (<1) |
| Conditioning regimen | |
| Fludarabine/busulfan | 150 (45) |
| Fludarabine/melphalan | 103 (31) |
| TBI/cyclophosphamide based | 64 (19) |
| Other | 13 (4) |
| GVHD prophylaxis | |
| Tacrolimus/methotrexate based | 116 (35) |
| Tacrolimus alone | 85 (26) |
| Tacrolimus/MMF based | 49 (15) |
| Cyclosporine based | 28 (8) |
| CD34 selection | 12 (4) |
| Posttransplant cyclophosphamide based | 12 (4) |
| Other | 28 (8) |
| ATG/alemtuzumab | |
| ATG | 135 (41) |
| Alemtuzumab | 80 (24) |
| Neither | 113 (34) |
| Missing | 2 (<1) |
| Year of transplant | |
| 2011 | 5 (2) |
| 2012 | 16 (5) |
| 2013 | 45 (14) |
| 2014 | 85 (26) |
| 2015 | 68 (21) |
| 2016 | 51 (15) |
| 2017 | 60 (18) |
| Transplant center | |
| MD Anderson | 23 (7) |
| Memorial Sloan Kettering Cancer Center | 14 (4) |
| University of California San Francisco | 136 (41) |
| University of Chicago | 105 (32) |
| University of Minnesota | 41 (12) |
| University of Nebraska | 11 (3) |
| Indication for GA | |
| Research | 177 (54) |
| Systematic standard of care | 116 (35) |
| Nonsystematic standard of care | 37 (11) |
ALL, acute lymphoid leukemia; CML, chronic myelogenous leukemia; GVHD, graft-versus-host disease; HCT-CI, Hematopoietic Cell Transplant-Comorbidity Index; MDS, myelodysplastic syndrome; MM, multiple myeloma; MMF, mycophenolate mofetil; MPN, myeloproliferative neoplasm; NHL, non-Hodgkin lymphoma; PCD, plasma cell dyscrasia; TBI, total body irradiation.
*
Other related: this includes 9 haploidentical transplants.